NEW YORK, August 6, 2015 /PRNewswire/ --
Equity Research Institute has initiated coverage on the
following equities: Omnicare Inc. (NYSE: OCR), DaVita HealthCare
Partners Inc. (NYSE: DVA), HEALTHSOUTH Corporation (NYSE: HLS),
Healthways Inc. (NASDAQ: HWAY), and MEDNAX Inc. (NYSE: MD). Free
research report on Omnicare can be accessed at
https://www.EquityResearchInstitute.com/reports?keyword=OCR On
Wednesday, August 05, 2015, the
NASDAQ Composite ended at 5,139.94, up 0.67%, the Dow Jones
Industrial Average edged 0.06% lower, to finish the day at
17,540.47, and the S&P 500 closed at 2,099.84, up 0.31%. The
gains were broad based as six out of nine sectors ended the session
in positive. Register for your complimentary reports at the links
given below.
Omnicare Inc.'s stock edged 0.22% higher, to close the day at
$97.10. The stock recorded a trading
volume of 1.98 million shares, much below its three months average
volume of 2.51 million shares. Over the last one month and over the
past three months, Omnicare Inc.'s shares have gained 2.63% and
7.58%, respectively. Furthermore, the stock has surged 33.84% since
the start of this year. The company's shares are trading 2.18%
above their 50-day moving average and 20.65% above their 200-day
moving average. Additionally, Omnicare Inc. traded at a PE ratio of
59.57 and has a Relative Strength Index (RSI) of 80.89. Sign up and
read the free notes on OCR at:
https://www.EquityResearchInstitute.com/reports?keyword=OCR
On Wednesday, shares in DaVita HealthCare Partners Inc. recorded
a trading volume of 1.80 million shares, higher than their three
months average volume of 0.98 million shares. The stock ended the
day 0.36% higher at $80.49. Shares of
the company traded at a PE ratio of 40.86. Although, DaVita
HealthCare Partners Inc.'s stock has lost 1.13% in the previous
three months, it has advanced 1.04% in the last one month and 6.27%
on YTD basis. The company is trading above its 200-day moving
average by 2.55%. Furthermore, shares of DaVita HealthCare Partners
Inc. have an RSI of 55.90. The complimentary notes on DVA can be
downloaded in PDF format at:
https://www.EquityResearchInstitute.com/reports?keyword=DVA
HEALTHSOUTH Corp.'s stock lost 1.34%, to close Wednesday's
session at $46.43. The stock recorded
a trading volume of 1.49 million shares, above its three months
average volume of 0.81 million shares. Over the previous three
months and since the beginning of 2015, HEALTHSOUTH Corp.'s shares
have surged 11.05% and 20.72%, respectively. However, the stock has
lost 1.25% in the last one month. The company is trading 1.58% and
7.83% above its 50-day and 200-day moving averages, respectively.
Furthermore, HEALTHSOUTH Corp.'s stock traded at a PE ratio of
26.08 and has an RSI of 54.03. Register for free on Equity Research
Institute and access the latest research on HLS at:
https://www.EquityResearchInstitute.com/reports?keyword=HLS
Healthways Inc.'s stock finished Wednesday's session 1.23%
higher at $13.15. A total of 0.31
million shares were traded, which was below its three months
average volume of 0.70 million shares. Over the previous three
months and since the start of this year, Healthways Inc.'s shares
have lost 21.91% and 33.85%, respectively. However, the stock has
gained 12.39% in the last one month. The company's shares are
trading below their 50-day and 200-day moving averages by 2.46% and
24.51%, respectively. Healthways Inc.'s stock traded at a PE ratio
of 219.17 and has an RSI of 52.20. The complete research on HWAY is
available for free at:
https://www.EquityResearchInstitute.com/reports?keyword=HWAY
On Wednesday, shares in MEDNAX Inc. ended the session 0.66%
higher at $85.10. The stock reported
a trading volume of 0.50 million shares, below its three months
average volume of 0.65 million shares. Shares of the company traded
at a PE ratio of 25.25. MEDNAX Inc.'s shares have surged 11.55% in
the last one month, 20.83% in the previous three months and 28.72%
on YTD basis. The company is trading 13.25% above its 50-day moving
average and 22.14% above its 200-day moving average. Moreover,
shares of MEDNAX Inc. have an RSI of 89.75. Free in-depth research
on MD is available at:
https://www.EquityResearchInstitute.com/reports?keyword=MD
--
About Equity Research Institute:
Equity Research Institute ("ERI") produces regular sponsored and
non-sponsored reports, articles, stock market blogs, and popular
investment newsletters covering equities listed on NYSE and NASDAQ
and micro-cap stocks. ERI has two distinct and independent
departments. One department produces non-sponsored analyst
certified content generally in the form of press releases, articles
and reports covering equities listed on NYSE and NASDAQ and the
other produces sponsored content (in most cases not reviewed by a
registered analyst), which typically consists of compensated
investment newsletters, articles and reports covering listed stocks
and micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
ERI has not been compensated; directly or indirectly; for
producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a third
party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "CFA®"),
provides necessary guidance in preparing the document templates.
The Reviewer has reviewed and revised the content, as necessary,
based on sound investment judgment and publicly available
information which is believed to be reliable. The Reviewer and the
CFA® have not performed any independent investigations or forensic
audits to validate the information herein. Unless otherwise noted,
any content outside of this document has no association with the
Author, the Reviewer, or the CFA® (collectively referred to as the
"Production Team") in any way. The Production Team is compensated
on a fixed monthly basis and do not hold any positions of interest
in any of the securities mentioned herein.
NO WARRANTY
ERI, the Author, the Reviewer and the CFA® (collectively
referred to as the "Publishers") are not responsible for any error
which may be occasioned at the time of printing of this document or
any error, mistake or shortcoming. No liability is accepted by the
Publishers whatsoever for any direct, indirect or consequential
loss arising from the use of this document. The Publishers
expressly disclaim any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance
placed on the information in this document. Additionally, the
Publishers do not (1) guarantee the accuracy, timeliness,
completeness or correct sequencing of the information, or (2)
warrant any results from use of the information. The included
information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither ERI nor any party affiliated with us is a
registered investment adviser or broker-dealer with any agency or
in any jurisdiction whatsoever. To download our report(s), read our
disclosures, or for more information, visit
http://www.equityresearchinstitute.com.
RESTRICTIONS
ERI is not available to residents of Belarus, Cuba, Canada,
Iran, North Korea, Sudan, Syria
or Somalia. Do not send email to
robottrap (at) equityresearchinstitute.com.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE www.equityresearchinstitute.com
